EugÃ¨ne P Van Puijenbroek

List of Publications by Year
in descending order

109 papers	3,268 citations	236925 25 h-index	168389 53 g-index
110 all docs	110 docs citations	110 times ranked	2426 citing authors

#	Article	IF	Citations
1	A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2002, 11, 3-10.	1.9	822
2	The role of data mining in pharmacovigilance. Expert Opinion on Drug Safety, 2005, 4, 929-948.	2.4	211
3	Use of Measures of Disproportionality in Pharmacovigilance. Drug Safety, 2002, 25, 453-458.	3.2	138
4	On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Statistics in Medicine, 2002, 21, 2027-2044.	1.6	115
5	Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. British Journal of Clinical Pharmacology, 1999, 47, 689-693.	2.4	108
6	Detecting drugâ€“drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. European Journal of Clinical Pharmacology, 2000, 56, 733-738.	1.9	105
7	Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions. Drug Safety, 2003, 26, 293-301.	3.2	104
8	Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. British Journal of Clinical Pharmacology, 2019, 85, 1507-1515.	2.4	89
9	Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. European Journal of Clinical Pharmacology, 2010, 66, 1143-1150.	1.9	65
10	The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis. Drug Safety, 2017, 40, 607-614.	3.2	63
11	Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. British Journal of Clinical Pharmacology, 2001, 52, 579-586.	2.4	54
12	Adverse drug reaction reports of patients and healthcare professionalsâ€"differences in reported information. Pharmacoepidemiology and Drug Safety, 2015, 24, 152-158.	1.9	54
13	Hyponatraemia as an Adverse Drug Reaction of Antipsychotic Drugs. Drug Safety, 2010, 33, 569-578.	3.2	51
14	Different Risks for NSAID-Induced Anaphylaxis. Annals of Pharmacotherapy, 2002, 36, 24-29.	1.9	50
15	The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: caseâ€“control study. Pharmacoepidemiology and Drug Safety, 2011, 20, 286-291.	1.9	47
16	Influence of Chemical Structure on Hypersensitivity Reactions Induced by Antiepileptic Drugs. Drug Safety, 2008, 31, 695-702.	3.2	42
17	The Impact of Experiencing Adverse Drug Reactions on the Patientâ€™s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands. Drug Safety, 2016, 39, 769-776.	3.2	40
18	Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study. Drug Safety, 2020, 43, 489-495.	3.2	34

#	Article	IF	Citations
19	Photo-onycholysis associated with the use of doxycycline. BMJ: British Medical Journal, 2004, 329, 265.1.	2.3	33
20	Intensive Monitoring of Pregabalin. Drug Safety, 2011, 34, 221-231.	3.2	33
21	Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug Safety, 2020, 43, 339-350.	3.2	30
22	Reporting of Adverse Drug Reactions by General Practitioners. Drug Safety, 2009, 32, 851-858.	3.2	29
23	Longitudinal monitoring of the safety of drugs by using a webâ€based system: the case of pregabalin. Pharmacoepidemiology and Drug Safety, 2011, 20, 591-597.	1.9	29
24	Uterine Perforation with the Levonorgestrel-Releasing Intrauterine Device. Drug Safety, 2011, 34, 83-88.	3.2	28
25	Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins. Pharmacoepidemiology and Drug Safety, 2010, 19, 26-32.	1.9	27
26	Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) or Hyponatraemia Associated with Valproic Acid. Drug Safety, 2010, 33, 47-55.	3.2	27
27	Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases. Drug Safety, 2018, 41, 859-869.	3.2	27
28	Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands. Drug Safety, 2010, 33, 1097-1108.	3.2	26
29	A global view of undergraduate education in pharmacovigilance. European Journal of Clinical Pharmacology, 2017, 73, 891-899.	1.9	26
30	Effectiveness of Pharmacovigilance Training of General Practitioners. Drug Safety, 2011, 34, 755-762.	3.2	25
31	Intensive monitoring of duloxetine: results of a web-based intensive monitoring study. European Journal of Clinical Pharmacology, 2013, 69, 209-215.	1.9	24
32	Important information regarding reporting of adverse drug reactions: a qualitative study. International Journal of Pharmacy Practice, 2014, 22, 231-233.	0.6	23
33	Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study. Drug Safety, 2017, 40, 409-418.	3.2	22
34	Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors. Drug Safety, 2018, 41, 677-683.	3.2	22
35	Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome?. Pharmacoepidemiology and Drug Safety, 2001, 10, 135-142.	1.9	20
36	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. Drug Safety, 2020, 43, 917-925.	3.2	20

#	Article	IF	Citations
37	Data mining in pharmacovigilance: lessons from phantom ships. European Journal of Clinical Pharmacology, 2006, 62, 967-970.	1.9	19
38	Drug-Related Nephrotoxic and Ototoxic Reactions. Drug Safety, 2008, 31, 877-884.	3.2	19
39	Pharmacovigilance Skills, Knowledge and Attitudes in our Future Doctors â€“ A Nationwide Study in the Netherlands. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 475-481.	2.5	19
40	A prediction modelâ€based algorithm for computerâ€assisted database screening of adverse drug reactions in the Netherlands. Pharmacoepidemiology and Drug Safety, 2018, 27, 199-205.	1.9	19
41	Time course, outcome and management of adverse drug reactions associated with metformin from patientâ€™s perspective: a prospective, observational cohort study in the Netherlands. European Journal of Clinical Pharmacology, 2016, 72, 615-622.	1.9	18
42	Web-based questionnaires to assess perinatal outcome proved to be valid. Journal of Clinical Epidemiology, 2017, 90, 136-143.	5.0	18
43	Patientsâ€™ Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana. Drug Safety, 2017, 40, 911-921.	3.2	18
44	Do pharmacistsâ€™ reports of adverse drug reactions reflect patientsâ€™ concerns?. International Journal of Clinical Pharmacy, 2004, 26, 155-159.	1.4	17
45	Expectations for Feedback in Adverse Drug Reporting by Healthcare Professionals in the Netherlands. Drug Safety, 2011, 35, 1.	3.2	17
46	When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection. Clinical Pharmacology and Therapeutics, 2018, 103, 296-303.	4.7	17
47	Impact of a Forced Dose-Equivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study. Thyroid, 2020, 30, 821-828.	4.5	17
48	The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles. International Journal of Clinical Pharmacy, 2003, 25, 260-263.	1.4	16
49	Clindamycin and taste disorders. British Journal of Clinical Pharmacology, 2007, 64, 542-545.	2.4	16
50	The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 17-26.	3.0	16
51	Spontaneous ADR Reports as a Trigger for Pharmacogenetic Research. Drug Safety, 2009, 32, 255-264.	3.2	15
52	Fever Following Immunization with Influenza A (H1N1) Vaccine in Children. Drug Safety, 2010, 33, 1109-1115.	3.2	15
53	Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database. British Journal of Clinical Pharmacology, 2018, 84, 1514-1524.	2.4	15
54	Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and nonâ€diabetic patients. British Journal of Clinical Pharmacology, 2015, 79, 870-871.	2.4	14

#	Article	IF	Citations
55	The value of timeâ€toâ€onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands. Pharmacoepidemiology and Drug Safety, 2016, 25, 1361-1367.	1.9	14
56	The validity and reliability of a signal impact assessment tool. Pharmacoepidemiology and Drug Safety, 2016, 25, 815-819.	1.9	11
57	The International Pharmacy Game: A Comparison of Implementation in Seven Universities World-Wide. Pharmacy (Basel, Switzerland), 2021, 9, 125.	1.6	11
58	Myopathy Due to Statin/Fibrate Use in the Netherlands. Annals of Pharmacotherapy, 2002, 36, 1957-1960.	1.9	10
59	Slipped capital femoral epiphyses associated with the withdrawal of a gonadotrophin releasing hormone. BMJ: British Medical Journal, 2004, 328, 1353.	2.3	10
60	Experiences with the Use of Varenicline in Daily Practice in the Netherlands: A Prospective, Observational Cohort Study. Drug Safety, 2014, 37, 449-457.	3.2	10
61	Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: Description of a prospective cohort and spontaneously reported pregnancyâ€related adverse reactions in the Netherlands. Birth Defects Research Part A: Clinical and Molecular Teratology, 2014, 100, 731-738.	1.6	10
62	Numbers of spontaneous reports: how to use and interpret?. British Journal of Clinical Pharmacology, 2021, , .	2.4	10
63	Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors. JAMA Network Open, 2022, 5, e228224.	5.9	10
64	Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. Pharmacoepidemiology and Drug Safety, 2006, 15, 99-105.	1.9	9
65	Spontaneous ejaculation with the use of noradrenergic reuptake inhibitors. European Journal of Clinical Pharmacology, 2012, 68, 1461-1462.	1.9	9
66	Feedback for patients reporting adverse drug reactions; satisfaction and expectations. Expert Opinion on Drug Safety, 2015, 14, 625-632.	2.4	9
67	Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review. Seminars in Nuclear Medicine, 2019, 49, 382-410.	4.6	9
68	Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. Expert Opinion on Drug Safety, 2020, 19, 1617-1624.	2.4	9
69	Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africaâ€"Ethiopia, Kenya, Rwanda, and Tanzania. International Journal of Environmental Research and Public Health, 2021, 18, 1941.	2.6	9
70	Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports. Drug Safety, 2022, 45, 145-153.	3.2	9
71	Post Launch Monitoring of food products: What can be learned from pharmacovigilance. Regulatory Toxicology and Pharmacology, 2007, 47, 213-220.	2.7	8
72	Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction. Pharmacoepidemiology and Drug Safety, 2008, 17, 76-81.	1.9	8

#	Article	IF	Citations
73	Representativeness of diabetes patients participating in a webâ€based adverse drug reaction monitoring system. Pharmacoepidemiology and Drug Safety, 2013, 22, 250-255.	1.9	8
74	Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care. Pharmacoepidemiology and Drug Safety, 2019, 28, 1175-1179.	1.9	8
75	Relationship Between Structural Alerts in NSAIDs and Idiosyncratic Hepatotoxicity: An Analysis of Spontaneous Report Data from the WHO Database. Drug Safety, 2015, 38, 511-515.	3.2	7
76	Immune-mediated inflammatory disease patientsâ€™ preferences in adverse drug reaction information regarding biologics. Expert Opinion on Drug Safety, 2020, 19, 1049-1054.	2.4	6
77	Hearing Impairment Associated with Oral Terbinafine Use. Drug Safety, 2012, 35, 685-691.	3.2	5
78	Discontinuation of metformin to prevent metformin-induced high colonic FDG uptake: is 48Âh sufficient?. Annals of Nuclear Medicine, 2020, 34, 833-839.	2.2	5
79	Hearing Impairment Associated with Oral Terbinafine Use. Drug Safety, 2012, 35, 685-691.	3.2	5
80	Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals. Expert Opinion on Drug Safety, 2022, 21, 699-706.	2.4	5
81	Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. Annals of the Rheumatic Diseases, 2022, 81, 597-599.	0.9	5
82	Mirtazapine-induced arthralgia. British Journal of Clinical Pharmacology, 2005, 60, 570-572.	2.4	4
83	Monitoring adverse events of vaccines against Mexican flu. International Journal of Risk and Safety in Medicine, 2011, 23, 81-87.	0.6	4
84	Assessment of medication use during pregnancy by Web-based questionnaires, pharmacy records and serum screening. Reproductive Toxicology, 2019, 84, 93-97.	2.9	4
85	Patient preferences and expectation for feedback on adverse drug reaction reports submitted in Ghana. Ghana Medical Journal, 2019, 53, 150.	0.4	4
86	Time to onset in statistical signal detection revisited: A followâ€up study in longâ€term onset adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2019, 28, 1283-1289.	1.9	4
87	Male Sexual Health and Reproduction in Cutaneous Immune-Mediated Diseases: A Systematic Review. Sexual Medicine Reviews, 2020, 9, 423-433.	2.9	4
88	Patient-Reported Adverse Events of Radiopharmaceuticals: A Prospective Study of 1002 Patients. Drug Safety, 2021, 44, 211-222.	3.2	4
89	Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy. Frontiers in Medical Technology, 2021, 3, 629750.	2.5	4
90	Evaluation of pharmacovigilance systems for reporting medication errors in Africa and the role of patients using a mixed-methods approach. PLoS ONE, 2022, 17, e0264699.	2.5	4

#	Article	IF	Citations
91	Spontaneous Reports and Pharmacogenetics. Drug Safety, 2009, 32, 357-358.	3.2	3
92	Parametric time-to-onset models were developed to improve causality assessment of adverse drug reactions from antidiabetic drugs. Journal of Clinical Epidemiology, 2015, 68, 1423-1431.	5.0	3
93	Actions in response to drug safety signalsÂarising from a spontaneous reportingÂsystem: Retrospective studyÂinÂTheÂNetherlands. International Journal of Risk and Safety in Medicine, 2016, 28, 115-123.	0.6	3
94	Contraindicated use of 5â€alphaâ€reductase inhibitors in women. British Journal of Clinical Pharmacology, 2017, 83, 429-431.	2.4	3
95	Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy, 2021, 22, 923-935.	1.8	3
96	Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review. Vaccines, 2021, 9, 111.	4.4	3
97	Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients. Expert Opinion on Drug Safety, 2022, 21, 417-423.	2.4	3
98	Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives. Drug Safety, 2019, 42, 683-687.	3.2	2
99	Stakeholdersâ€™ perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. Expert Opinion on Drug Safety, 2020, 19, 1521-1528.	2.4	2
100	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. Journal of Rheumatology, 2021, 48, 1388-1394.	2.0	2
101	Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 27.	3.9	2
102	Broadening the Scope of Pharmacovigilance. , 2017, , 131-144.		1
103	Safety profile of non-vitamin K oral anticoagulants (NOACs) from a patient perspective: a web-based cohort event monitoring study. Expert Opinion on Drug Safety, 2019, 18, 869-874.	2.4	1
104	Anaphylactic Reaction to Tc-99m Macrosalb. Drug Safety - Case Reports, 2019, 6, 4.	0.9	1
105	Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire. Drug Safety, 2020, 43, 319-328.	3.2	1
106	Retroperitoneal fibrosis and Î²â€blocking agents: Is there an association?. British Journal of Clinical Pharmacology, 2021, 87, 2891-2901.	2.4	1
107	Electronic Health Recordâ€“Triggered Research Infrastructure Combining Real-world Electronic Health Record Data and Patient-Reported Outcomes to Detect Benefits, Risks, and Impact of Medication: Development Study. JMIR Medical Informatics, 2022, 10, e33250.	2.6	1
108	Response to the validity and reliability of a signal impact assessment tool: statistical issue to avoid misinterpretation. Pharmacoepidemiology and Drug Safety, 2016, 25, 1217-1217.	1.9	0

#	Article	IF	Citations
109	Patientsâ€™ perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert Opinion on Drug Safety, 2021, 20, 1-8.	2.4	0